News and Press Releases
About the CF Foundation | CFTR Modulators | Genetic Therapies FDA Expands Use of Orkambi® to Children Ages 6 to 11 With CF

The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.

| 2 min read